Redefining Perfusion Imaging for Brain Tumor Assessment
A new level of quality for confident assessments
Making confident assessments that have a direct impact on patients’ treatment and wellbeing requires tools that you can rely on.
Our novel approach to perfusion imaging, based on more than 15 years of research in brain perfusion, provides you with perfusion imaging that is simple-to-use, reproducible, and easy-to-read, enabling you to gain deeper insights for brain tumor assessment with perfusion maps you can trust.
Advanced technology, simplicity of use
CERCARE Perfusion minimizes user interaction. You get a fully-automated perfusion imaging solution for brain tumors assessment that is fast, reliable and works with your existing protocols.
Easy integration into your clinical workflow
CERCARE Perfusion has multi-vendor compatibility and can be integrated into your clinical workflow through your PACS or via a range of 3rd party platforms. Choose the integration that fits you best. It is as easy as it can be.
Clinical implementation example
Unique insights into tissue oxygenation in brain tumors
We redefine neuroimaging by challenging current standards.
Our technology accounts for capillary flow generating reliable parametric maps that do not only reflect the cerebral blood flow and the cerebral blood volume but provide additional insights with unique maps of capillary transit time heterogeneity, oxygen extraction fraction, and metabolic rate of oxygen that have already shown to provide invaluable insights for tumor analysis and grading**.
So you can make fast and more detailed assessments. Every time.
CERCARE Perfusion: A Novel Approach to Perfusion Imaging Technology for Oncology Assessment
Learn more about our novel approach to perfusion imaging that provides deeper insights for tumor prognosis and assessment. Download our whitepaper.
Find out more:
*CERCARE Perfusion consists of Cercare Medical Neurosuite and one module – Capillary Function. Both are CE-marked according to the European Medical Device Directive 93/42/EEC, and developed/manufactured by: Cercare Medical ApS registered at Inge Lehmanns Gade 10, 8000 Aarhus C, Denmark.
**Tietze A, Mouridsen K, Lassen-Ramshad Y, Østergaard L. Perfusion MRI derived indices of microvascular shunting and flow control correlate with tumor grade and outcome in patients with cerebral glioma. PLoS One. 2015 Apr 13;10(4):e0123044. doi: 10.1371/journal.pone.0123044.